% alzhub.org library filter
% Source: https://alzhub.org/research?institution=I4210152456
% 11 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{teng2022-35696185,
  author  = {Teng, E. and Manser, P. T. and Pickthorn, K. and Brunstein, F. and Blendstrup, M. and Sanabria Bohorquez, S. and Wildsmith, K. R. and Toth, B. and others},
  title   = {{Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.1375},
  pmid    = {35696185},
  url     = {https://doi.org/10.1001/jamaneurol.2022.1375}
}

@article{mummery2026-41787076,
  author  = {Mummery, C. J. and Mayorga, A. J. and Simmons, A. and Chow, T. W. and Burgess, B. and Nguyen, T. and Gao, J. and Budda, B. and Park, L. Q. and Gupta, R. and Li, C. and Shi, L. and others},
  title   = {{The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial}},
  journal = {Nature Medicine},
  year    = {2026},
  doi     = {10.1038/s41591-026-04273-1},
  pmid    = {41787076},
  url     = {https://doi.org/10.1038/s41591-026-04273-1}
}

@article{long2024-39444037,
  author  = {Long, H. and Simmons, A. and Mayorga, A. and Burgess, B. and Nguyen, T. and Budda, B. and Rychkova, A. and Rhinn, H. and others},
  title   = {{Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01599-1},
  pmid    = {39444037},
  url     = {https://doi.org/10.1186/s13195-024-01599-1}
}

@article{hong2016-27033548,
  author  = {Hong, S. and Beja-Glasser, V. F. and Nfonoyim, B. M. and Frouin, A. and Li, S. and Ramakrishnan, S. and Merry, K. M. and Shi, Q. and others},
  title   = {{Complement and microglia mediate early synapse loss in Alzheimer mouse models}},
  journal = {Science (New York, N.Y.)},
  year    = {2016},
  doi     = {10.1126/science.aad8373},
  pmid    = {27033548},
  url     = {https://doi.org/10.1126/science.aad8373}
}

@article{wang2020-32579671,
  author  = {Wang, S. and Mustafa, M. and Yuede, C. M. and Salazar, S. V. and Kong, P. and Long, H. and Ward, M. and Siddiqui, O. and others},
  title   = {{Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model}},
  journal = {The Journal of experimental medicine},
  year    = {2020},
  doi     = {10.1084/jem.20200785},
  pmid    = {32579671},
  url     = {https://doi.org/10.1084/jem.20200785}
}

@article{cignarella2020-32772264,
  author  = {Cignarella, F. and Filipello, F. and Bollman, B. and Cantoni, C. and Locca, A. and Mikesell, R. and Manis, M. and Ibrahim, A. and others},
  title   = {{TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis}},
  journal = {Acta neuropathologica},
  year    = {2020},
  doi     = {10.1007/s00401-020-02193-z},
  pmid    = {32772264},
  url     = {https://doi.org/10.1007/s00401-020-02193-z}
}

@article{boxer2020-31668596,
  author  = {Boxer, A. L. and Gold, M. and Feldman, H. and Boeve, B. F. and Dickinson, S. L. and Fillit, H. and Ho, C. and Paul, R. and others},
  title   = {{New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2020},
  doi     = {10.1016/j.jalz.2019.06.4956},
  pmid    = {31668596},
  url     = {https://doi.org/10.1016/j.jalz.2019.06.4956}
}

@article{patterson2024-38695172,
  author  = {Patterson, M. T. and Xu, Y. and Hillman, H. and Osinski, V. and Schrank, P. R. and Kennedy, A. E. and Barrow, F. and Zhu, A. and others},
  title   = {{Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report}},
  journal = {Arteriosclerosis, thrombosis, and vascular biology},
  year    = {2024},
  doi     = {10.1161/atvbaha.124.320797},
  pmid    = {38695172},
  url     = {https://doi.org/10.1161/atvbaha.124.320797}
}

@article{rhinn2022-35039149,
  author  = {Rhinn, H. and Tatton, N. and McCaughey, S. and Kurnellas, M. and Rosenthal, A.},
  title   = {{Progranulin as a therapeutic target in neurodegenerative diseases}},
  journal = {Trends in pharmacological sciences},
  year    = {2022},
  doi     = {10.1016/j.tips.2021.11.015},
  pmid    = {35039149},
  url     = {https://doi.org/10.1016/j.tips.2021.11.015}
}

@article{schwabe2020-32535152,
  author  = {Schwabe, T. and Srinivasan, K. and Rhinn, H.},
  title   = {{Shifting paradigms: The central role of microglia in Alzheimer's disease}},
  journal = {Neurobiology of disease},
  year    = {2020},
  doi     = {10.1016/j.nbd.2020.104962},
  pmid    = {32535152},
  url     = {https://doi.org/10.1016/j.nbd.2020.104962}
}

@article{cruchaga2021-91194d89,
  author  = {Cruchaga, C. and Sung, Y. J. and Yang, C. and Wang, F. and Suhy, A. and Norton, J. and Novotny, B. and Etelleb, A. and others},
  title   = {{Multi-tissue proteomics identifies molecular signatures for sporadic and genetically defined Alzheimer disease cases}},
  journal = {Research Square},
  year    = {2021},
  doi     = {10.21203/rs.3.rs-923492/v1},
  url     = {https://doi.org/10.21203/rs.3.rs-923492/v1}
}